Root Admin Guide Posted June 1, 2019 Root Admin Report Share Posted June 1, 2019 "Sarecycline (trade name Seysara; development code WC-3035) is a tetracycline-derived antibiotic. In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris". Wikipedia "Sarecycline (Seysara™) is an oral, once-daily, tetracycline-class drug for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years. The drug was developed by Paratek and Allergen and later acquired by Almirall S.A. (a Barcelona-based pharmaceutical company focused on medical dermatology). Sarceycline tablets were approved in early October 2018 and are planned to be available for patients in January 2019. Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified for this formulation. There are currently no clinical trials underway assessing sarecycline in rosacea." "There are currently no clinical trials underway assessing sarecycline in rosacea.....For moderate to severe and inflammatory acne vulgaris, oral antibacterials are standard care components, with tetracyclines and macrolides usually preferred. However, these agents have certain limitations, among which are photosensitivity (tetracyclines), adverse vestibular effects (minocycline), gastrointestinal disturbances (particularly with macrolides and doxycycline), dysbiosis and microbial resistance concerns." Drugs. 2019; 79(3): 325–329.Sarecycline: First Global ApprovalEmma D. Deeks There is now a paper showing the results of "pharmacokinetics and safety studies": "14 Phase I pharmacokinetics and safety studies were performed on 378 patients with moderate-to-severe acne vulgaris exposed to sarecycline, with and without food (tablets and capsules)." Future Microbiol. 2019 Sep; 14(14): 1235–1242.Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris Angela Yen Moore, Jean Elizze M Charles, and Stephen Moore Link to comment Share on other sites More sharing options...
Root Admin Guide Posted April 27, 2021 Author Root Admin Report Share Posted April 27, 2021 "Altogether, these data illustrate the great potential of sarecycline for treatment of acne vulgaris with a targeted spectrum of activity, lower risk of antibiotic resistance, and fewer AEs than other tetracycline-class antibiotics. Narrow-spectrum antibiotics offer an alternative for clinicians to improve antibiotic stewardship and limit bacterial resistance." Antibiotics (Basel). 2021 Apr; 10(4): 439.Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation Christopher G. Bunick, Jonette Keri, S. Ken Tanaka, Nika Furey, Giovanni Damiani, Jodi L. Johnson,8 and Ayman Grada Link to comment Share on other sites More sharing options...
Root Admin Guide Posted December 27, 2021 Author Root Admin Report Share Posted December 27, 2021 "Sarecycline is an analogue of tetracycline specifically designed for the treatment of acne. It is available as an oral formulation to treat inflammatory lesions of moderate to severe non-nodular acne vulgaris. The main advantage of this new tetracycline is a higher selective activity against Cutinebacterium acnes comparative to older tetracyclines (doxycycline and minocycline) used in acne therapy. Due to this selectivity, the probability of developing antibiotic resistance is lower than minocycline and doxycycline." Pharmaceutics. 2021 Dec; 13(12): 2085.The Development of Third-Generation Tetracycline Antibiotics and New Perspectives Aura Rusu and Emanuela Lorena Buta Link to comment Share on other sites More sharing options...
Root Admin Guide Posted June 29, 2022 Author Root Admin Report Share Posted June 29, 2022 Sarecyline is defined as a "narrow-spectrum tetracycline derivative" as opposed to doxycycline or minocycline which are defined as broad-spectrum tetracyclines. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now